Table 1.
Baseline characteristics.
| Total | Sodium Butyrate | Placebo | |
|---|---|---|---|
| Number | 53 (100) | 28 (53) | 25 (47) |
| Site (Denmark) | 41 (77) | 22 (79) | 19 (76) |
| Sex (Female) | 23 (43) | 11 (39) | 12 (48) |
| Age, years | 54 ± 13 | 56 ± 11 | 52 ± 15 |
| Diabetes duration, years | 30 ± 15 | 29 ± 17 | 32 ± 14 |
| Current smoking | 7 (13) | 0 | 7 (28) |
| Body Mass Index, kg/m2 | 29 ± 5.8 | 30 ± 6.1 | 29 ± 5.7 |
| Systolic blood pressure, mm Hg | 135 ± 18 | 136 ± 15 | 134 ± 21 |
| Diastolic blood pressure, mm Hg | 78 ± 10 | 80 ± 10 | 77 ± 10 |
| Urinary albumin creatinine ratio, mg/g | 46 [14:121] | 39 [18:121] | 49 [14:121] |
| Normoalbuminuria | 21 (40) | 11 (39) | 10 (40) |
| Microalbuminuria | 24 (45) | 13 (46) | 12 (44) |
| Macroalbuminuria | 8 (15) | 4 (14) | 3 (12) |
| eGFR, mL/min/1.73 m2 | 84 ± 24 | 86 ± 26 | 8.1 ± 1.1 |
| HbA1c, % (mmol/mol) | 8.0 ± 1.0 | 8.0 ± 0.8 | 8.1 ± 1.1 |
| Fecal calprotectin ≥ 50 µg/g | 29 (55) | 14 (48) | 15 (52) |
| RASi treatment | 44 (83) | 23 (82) | 21 (84) |
| Statin treatment | 37 (70) | 21 (75) | 16 (64) |
| Metformin treatment | 10 (19) | 7 (25) | 3 (12) |
Data are shown as number (%), mean ± standard deviation, or median [Q1:Q3]. eGFR indicates estimated glomerular filtration rate; RASi, renin-angiotensin system inhibitor.